Novartis AG
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
Last updated:
Abstract:
Dosing regimens for the administration of complexes comprising IL-15/IL-15Ra in combination with an anti-PD-1 antibody molecule to patients are disclosed. Such dosing regimens can be used for preventing, treating and/or managing disorders such as cancer.
Status:
Application
Type:
Utility
Filling date:
19 Jan 2018
Issue date:
30 Jul 2020